CRBU Oct 2024 2.500 call
- Simply Wall St.
Caribou Biosciences, Inc. (NASDAQ:CRBU) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are probably feeling a little disappointed, since its shares...
- Zacks
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple milestones ahead -- -- $345.9 million in cash, cash
